Literature DB >> 29300804

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

L A Dunn, M G Fury, H Xiao, S S Baxi, E J Sherman, S Korte, C Pfister, S Haque, N Katabi, A L Ho, D G Pfister.   

Abstract

Entities:  

Year:  2018        PMID： 29300804      PMCID： PMC6888018          DOI： 10.1093/annonc/mdx801

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  1 in total

1.  Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.

Authors:  Hossein Taghizadeh; Agnieszka Maj-Hes; Gerald W Prager; Leonhard Müllauer; Robert M Mader
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.